Literature DB >> 1987214

Methodology of head-up tilt testing in patients with unexplained syncope.

A P Fitzpatrick1, G Theodorakis, P Vardas, R Sutton.   

Abstract

Prolonged 60 degree head-up tilt has been shown to be valuable in the investigation of unexplained syncope, diagnosing neurally mediated bradycardia/hypotension or malignant vasovagal syndrome. To evaluate the methodology of tilt testing, the following were examined: reproducibility of results, tilt duration, angle of tilt, method of tilt support and effect of age in patients and control subjects. Seventy-one patients with recurrent unexplained syncope underwent 60 min of 60 degree tilt; 53 (75%) had an abnormal test with vasovagal syncope at 24 +/- 10 min (mean +/- SD). Tilting to 60 degrees resulted in an abnormal test in only 2 (7%) of 27 control subjects without cardiovascular symptoms (p less than 0.001); and 5 (15%) of 34 patients with syncope and documented conduction tissue disease (p less than 0.001). Of 15 youthful fainters, 3 (20%) had vasovagal reactions as did 1 (8%) of 12 asymptomatic youthful control subjects. These 12 control subjects also underwent tilting with a saddle support and 7 (67%) had vasovagal reactions. It is concluded that the duration of tilting at 60 degrees should be 45 min (mean time to syncope +2 x SD in the 53 patients with abnormal results). Twenty percent of patients with an abnormal tilt test may not demonstrate syncope with repeat tilting. Saddle tilt testing in unexplained syncope may result in a loss of specificity. Tilting at less than 60 degrees results in a loss of sensitivity. Head-up tilt may be less useful in youthful subjects with vasovagal syncope than in other subjects.

Entities:  

Mesh:

Year:  1991        PMID: 1987214     DOI: 10.1016/0735-1097(91)90714-k

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  56 in total

1.  The Newcastle protocols for head-up tilt table testing in the diagnosis of vasovagal syncope, carotid sinus hypersensitivity, and related disorders.

Authors:  R A Kenny; D O'Shea; S W Parry
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

2.  Haemodynamic effects of increasing angle of head up tilt.

Authors:  A Zaidi; D Benitez; P A Gaydecki; A Vohra; A P Fitzpatrick
Journal:  Heart       Date:  2000-02       Impact factor: 5.994

3.  Determining the optimal pacing intervention rate for vasovagal syncope.

Authors:  A S Kurbaan; A C Franzén; Z Stack; D Heaven; G Mathur; R Sutton
Journal:  J Interv Card Electrophysiol       Date:  2000-12       Impact factor: 1.900

Review 4.  [Electrophysiologic diagnosis and therapy].

Authors:  Guido Ritscher; Helge Simon; Georg Nölker; Johannes Brachmann; Anil-Martin Sinha
Journal:  Med Klin (Munich)       Date:  2010-06

5.  [Commentary on the guidelines the diagnosis and the therapy of syncope--the European Society of Cardiology 2001 and the update 2004].

Authors:  K Seidl; A Schuchert; J Tebbenjohanns; W Hartung
Journal:  Z Kardiol       Date:  2005-09

Review 6.  Diagnosis and management of patients with blackouts.

Authors:  Adam P Fitzpatrick; Paul Cooper
Journal:  Heart       Date:  2006-04       Impact factor: 5.994

7.  Role of echocardiography in the evaluation of syncope: a prospective study.

Authors:  F P Sarasin; A-F Junod; D Carballo; S Slama; P-F Unger; M Louis-Simonet
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

Review 8.  Syncope: investigation and treatment.

Authors:  Satish R Raj; Robert S Sheldon
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

9.  Role of endogenous adenosine in vasovagal syncope.

Authors:  M Sinkovec; A Grad; P Rakovec
Journal:  Clin Auton Res       Date:  2001-06       Impact factor: 4.435

10.  Sex and age effects on cardiovascular autonomic function in healthy adults.

Authors:  Jean-Pierre Ndayisaba; Alessandra Fanciulli; Roberta Granata; Susanne Duerr; Florian Hintringer; Georg Goebel; Florian Krismer; Gregor K Wenning
Journal:  Clin Auton Res       Date:  2015-08-20       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.